Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

Howard H. Bailey, Michelle B. Mahoney, David S. Ettinger, William J. Maples, Paula M. Fracasso, Anne M. Traynor, Charles Erlichman, Scott H. Okuno

Research output: Contribution to journalArticlepeer-review

73 Scopus citations

Abstract

BACKGROUND. A multicenter Phase II study was performed to evaluate the clinical activity of an initial loading (150 mg every 6 hours × 4 doses) dose followed by continuous daily oral dosing (100 mg/day) of perifosine in patients with advanced soft tissue sarcomas (STSs). METHODS. Patients with measurable metastatic STS received perifosine as first-, second-, or third-line treatment and underwent disease assessment every 8 weeks until disease progression, excessive toxicity, or patient refusal. RESULTS. Twenty-three patients received 66 cycles (1 cycle = 4 weeks) of perifosine. One partial response of 9 months duration was observed. The overall 3 and 6 month progression-free survival was 22% and 9%. NCI CTC (v2.0) Grade 1 to 2 gastrointestinal toxicity or fatigue were the most common (>50% of subjects) toxicities observed. The steady-state plasma perifosine levels (Css) were similar to prior experience (mean 6 μg/mL). Patients with Css levels >6 μg/mL appeared more likely to remain on study past 2 months than those with levels <6 μg/mL. CONCLUSIONS. Despite not achieving the primary objective of ≥40% 6-month progression-free survival rate, optimism remains for this agent in STS patients. Prolonged responses in heavily pretreated STS patients continue to be observed with perifosine treatment. Continued assessment of perifosine in STS appears warranted, with special attention to specific histologies or tumor characteristics that might identify a more sensitive population and achieving perifosine Css levels >6 μg/mL.

Original languageEnglish (US)
Pages (from-to)2462-2467
Number of pages6
JournalCancer
Volume107
Issue number10
DOIs
StatePublished - Nov 15 2006

Keywords

  • Perifosine
  • Phase II trial
  • Sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma'. Together they form a unique fingerprint.

Cite this